Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.32 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.31 |
| ▸ | CHRNG | P07510 | 1/20 | 0.31 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CHRND | Q07001 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12926362 | 0.98 | SIGMAR1 (0.36) | SIGMAR1SOS1SOS2CHRNA1CHRNG | |
| SCHEMBL12958765 | 0.93 | SIGMAR1 (0.33) | SIGMAR1CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL90069 | 0.89 | — | — | |
| SCHEMBL15382218 | 0.85 | CHRNA1 (0.36) | SIGMAR1SOS1SOS2CHRNA1CHRNG | |
| SCHEMBL10062590 | 0.85 | CDC42BPB (0.34) | SIGMAR1CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL25049539 | 0.84 | USP2 (0.33) | SIGMAR1CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL18968285 | 0.84 | USP2 (0.33) | SIGMAR1CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL90414 | 0.83 | CHRNB2 (0.41) | SIGMAR1CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL10062591 | 0.83 | CHRNA1 (0.37) | SIGMAR1CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL21217000 | 0.83 | ALDH1A1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654831-B2 | Antiproliferative pyrimidine-based compounds | G1 THERAPEUTICS, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190135784-A1 | ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS | G1 THERAPEUTICS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| WO-2017040449-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-09 | — | — | WO | disclosed |
| US-7528132-B2 | immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease; indazolyl [1,2,4]triazine compounds | SCHERING CORPORATION (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080004257-A1 | Kinase inhibitors | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135784-A1 | ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS | MKI67, TYMS, TYMP | SIGMAR1 4499/4885SOS1 906/4885SOS2 1034/4885 |
| US-20080004257-A1 | Kinase inhibitors | MAP3K1, MAP3K13, MAP3K6 | SIGMAR1 4090/4885SOS1 1907/4885SOS2 2967/4885 |
| US-10654831-B2 | Antiproliferative pyrimidine-based compounds | MKI67, TYMS, TYMP | SIGMAR1 4499/4885SOS1 906/4885SOS2 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.